AMAG Pharmaceuticals Reschedules Third Quarter Financial Results Conference Call to November 4, 2011 at 8:00 a.m. ET

Conference Call Will Discuss Financial Results for the Third Quarter and Nine Months Ended September 30, 2011

Company to Provide Update on Expense Realignment and Restructuring Plans

LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company focused on the development and commercialization of a therapeutic compound to treat iron deficiency anemia, today announced that it will report unaudited consolidated financial results for the third quarter ended September 30, 2011 before the U.S. financial markets open on November 4, 2011. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET, during which management will discuss the company’s financial results, commercial progress, development programs and the Company’s expense realignment and restructuring plans as previously announced on October 21, 2011. This conference call was rescheduled from November 7, 2011 at 5:00 pm. ET.

Conference Call and Webcast Access

To access the conference call via telephone, dial (877) 412‐6083 from the United States or (702) 495-1202 for international access. A telephone replay of the conference call will be available from approximately 11:00 a.m. ET on November 4, 2011 until midnight November 7, 2011. To access the replay, dial (855) 859‐2056 from the United States or (404) 537‐3406 for international access. The pass code for the live call and the replay is 23448525. Following the conference call, the webcast replay will be available at approximately 11:00 a.m. ET and will be archived on the Investors section of the AMAG Pharmaceuticals, Inc. website through midnight December 4, 2011.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. For additional company information, please visit www.amagpharma.com.



CONTACT:

AMAG Pharmaceuticals, Inc.
Carol Miceli, 617‐498‐3361

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.